Margaret S. Sullivan
Meg Sullivan joined Ropes & Gray in 2015 as an associate in the corporate department. She practices primarily in the intellectual property transactions and life sciences groups.
During law school, Meg served as an article editor of the Harvard Journal of Law & Technology and participated in the Cyberlaw Clinic at Harvard’s Berkman Center for Internet & Society.
- Represented a global pharmaceutical company in obtaining an exclusive worldwide license to develop and commercialize an experimental medicine valued at over $1 billion in potential milestone, sales milestone and royalty payments. This complex transaction involved the interests of multiple parties and required the execution of several side letters, amendments to existing agreements, and the transition of ongoing clinical development.
- Represented an American multinational biotechnology company in obtaining an exclusive worldwide license to a Phase 2-ready experimental medicine worth over $700 million in upfront and potential milestone and royalty payments.
- Advised a major American university in an agreement with an education venture to help create, deliver and manage high-quality degree and certificate programs online.
- Represents Selecta Biosciences in connection with its commercial agreements.
- Represented Mersana Therapeutics, Inc. in its $33 million Series C-1 financing and continues to represent the company in connection with its general corporate matters and commercial agreements.
- Advised AMAG Pharmaceuticals in connection with its agreement with Palatin Technologies to gain exclusive North American rights to develop and commercialize Rekynda™ (bremelanotide), valued at up to $465 million in upfront, milestone and ongoing development payments, plus tiered royalties on net sales.
- Advised TSG Consumer Partners, TPG Capital, L.P. and other private equity firms with respect to intellectual property matters in connection with their investments in the consumer product, technology and industrial sectors.